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Abstract 
Urocortins (Ucns), peptides belonging to the corticotropin-releasing hormone (CRH) family, are classified into Ucn1, 
Ucn2, and Ucn3. They are involved in regulating several body functions by binding to two G protein-coupled recep-
tors: receptor type 1 (CRHR1) and type 2 (CRHR2). In this review, we provide a historical overview of research on Ucns 
and their receptors in the mammalian endocrine system. Although the literature on the topic is limited, we focused 
our attention particularly on the main role of Ucns and their receptors in regulating the hypothalamic–pituitary–adre-
nal and thyroid axes, reproductive organs, pancreas, gastrointestinal tract, and other tissues characterized by “diffuse” 
endocrine cells in mammals. The prominent function of these peptides in health conditions led us to also hypothesize 
an action of Ucn agonists/antagonists in stress and in various diseases with its critical consequences on behavior and 
physiology. The potential role of the urocortinergic system is an intriguing topic that deserves further in-depth investi-
gations to develop novel strategies for preventing stress-related conditions and treating endocrine diseases.
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Background
Urocortins (Ucns) belong to the corticotropin-releas-
ing hormone (CRH) family, which includes CRH, fish 
urotensin I, frog sauvagine, Ucn1, Ucn2 (or stresscopin-
related peptide), and Ucn3 (or stresscopin) [1–4]. This 
family is a critical regulator of the hypothalamic–pitui-
tary–adrenal (HPA) axis, leading to subsequent release of 
adrenocorticotropic hormone and corticosteroids [5, 6]. 
These 38–41-amino acid peptides are structurally related 
and are highly conserved among different animal spe-
cies [7, 8] (Fig. 1a). All peptides are encoded by separate 
genes. These peptides are found in the central nervous 
system (CNS) as well as in peripheral tissues including 
the digestive, cardiovascular, immune, reproductive, and 
endocrine systems [9–15]. The physiological effects of 
these peptides are mediated through seven transmem-
brane domain G-protein-coupled receptors (GPCRs): 
CRH receptor type 1 (CRHR1) and CRH receptor type 2 
(CRHR2). CRHR1 and CRHR2 have differential binding 
affinities to each of the CRH family members. CRHR1 
shows high affinity to CRH and Ucn1, but no appreci-
able binding affinity to Ucn2 and Ucn3. CRHR2 primar-
ily binds to Ucn1, Ucn2, and Ucn3 with greater affinity 
than to CRH [3, 8, 16] (Fig. 1c). These receptors also have 
different expression patterns in the central and periph-
eral tissues [17]. CRHR1 is primarily expressed in the 
CNS and the anterior pituitary. The CRHR2 receptor is 
expressed primarily in extra-CNS sites. Two separate 
genes encode the CRH receptors [18]. In addition to 
binding to two receptors, CRH-related peptides also bind 
to CRH-binding protein (CRHBP) [19]. CRHBP, a 37-kDa 
glycoprotein, limits ligand availability [20].
Ucns have been shown to be associated with a variety 
of physiological functions in different animal species, 
including domestic animals. These functions include 
stress [21–24], feeding behaviors and energy homeostasis 
[25–31], immune responses [32], cardiovascular regula-
tion [33–35], inflammation regulation [36], reproduction 
[37], and hormone release from the pituitary [38, 39].
Moreover, the presence of Ucns and their receptors was 
reported in several mammalian endocrine glands, thus 
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functions [13–15, 40, 41]. This review outlines existing 
knowledge on the expression and function of Ucns and 
their receptors in the mammalian endocrine system.
Search strategy
This review is based on a search in PubMed (http://www.
ncbi.nlm.nih.gov/pubme d) using the terms “urocortin, 
corticotropin-releasing hormone receptors, mammals, 
endocrine system”. The title and abstract of the obtained 
hits were evaluated and articles referring to urocortins 
in the endocrine system were obtained and assessed 
in detail. In addition, our own archives were used as a 
source of additional information. Our extensive experi-
ence with the expression of the urocortinergic system 
in the thyroid gland and testis of mammals was used to 
critically evaluate the literature.
Review
Urocortins and CRH‑receptors: general structure 
and biochemistry
Ucn1 is a 40-amino acid neuropeptide cloned from rat 
brain tissue that has a 45% similarity with CRH and a 60% 
identity with urotensin I [8] (Fig. 1a). Ucn1 is composed 
of a single alpha helix structure [42]. Human Ucn con-
sists of 124 amino acids, 80 of which form the “precursor 
peptide”. The amino acids Arg–Arg in position 81–82 and 
Lys-Gly in position 123–124 undergo proteolysis, consti-
tuting the site of detachment from the precursor and the 
C-terminal sequence, respectively. The mature Ucn1 pep-
tide is generated by cleavage of 42 amino acids from the 
C-terminus followed by amidation to eliminate the C-ter-
minal dipeptide Gly-Lys [43]. Since all the mammalian 
forms of Ucn1 discovered to date exhibit a high degree of 
sequence conservation, the functions of this peptide may 
be similar or identical across mammalian species. Ucn1 
has been identified in humans, rats, mice, hamsters, and 
sheep [8, 43, 44] with high sequence homology [44]. In 
addition, the mature Ucn1 sequence is highly conserved 
in different domestic animal species (99–100% iden-
tity to rat, mouse or human, and among them) (Fig. 1b). 
The gene encoding Ucn1 is located on the short arm of 
chromosome 2 (2p23–p21). The genomic structure of 
the Ucn1 gene is similar to that of the CRH gene, with 
two exons and one intron. The entire precursor protein 
is located entirely on the second exon [8, 43]. Ucn1 binds 
both CRH receptors with high affinity [42].
Ucn2 is a 38-amino acid peptide related to CRH that 
shows homology with rat and human CRH (has about 
34% similarity to rCRH and hCRH), hUcn1 (43%) and 
hUcn3 (37–40%) [3, 45]. Ucn2 and Ucn3, which were 
discovered during human genome mapping, are selective 
agonists of CRHR2 [45]. Human Ucn2 consists of two 
alpha helices, a short N–terminus and a long C-terminus, 
thus resulting in a helix-loop-helix structure. This struc-
ture is important for interaction with specific receptors 
[42]. The human gene encoding Ucn2 is located on chro-
mosome 3 and the transcription of this gene is upregu-
lated by glucocorticoids, suggesting that Ucn2 is involved 
in the stress response pathway [3, 46].
Ucn3 (also known as stresscopin) is composed of 38 
amino acids and has about 20–40% similarity to h/rCRH 
and Ucn1. Both Ucn2 and Ucn3 share a sequence similar-
ity of up to 40% [45]. The proline residue at position 11 
and alanine residues at positions 35 and 39 are charac-
teristic of CRHR2-selective ligands Ucn2 and Ucn3 [47] 
(Fig. 1a, c). Human Ucn3 consists of a small N-terminal 
helix and a long C-terminal alpha helix containing 20 
residues. This type of helix-loop-helix is critical for inter-
actions with specific receptors [42]. The links between 
the N- and C- terminal helices are thought to be crucial 
to ligand-receptor interactions [42]. The human gene 
encoding Ucn3 is located on chromosome 10 [48].
CRHR1 and CRHR2 are class B1 GPCRs consisting of 
seven transmembrane helices with an N-terminal extra-
cellular ligand-binding domain (ECD). CRHR1, a 415-
amino acid protein, shares 70% amino acidic sequence 
identity with CRHR2, but there is divergence at the 
N-terminal ECD. This is consistent with distinct phar-
macological properties and agonist selectivity of both 
receptors. CRHR1 binds CRH and Ucn1, but not Ucn2 or 
Ucn3, with similar high affinity (Fig. 1c). On the contrary, 
CRHR2 binds all Ucns with higher binding affinity than 
(See figure on previous page.)
Fig. 1 a Multiple alignment of the amino acid sequence of corticotropin-releasing hormone (CRH) and CRH-related peptides. The rat Ucn1 has 45% 
similarity to rCRH, Ucn2 has 34% similarity to CRH, Ucn3 has 26% similarity to CRH, frog Sauvagine has 50% similarity to CRH, fish Urotensin has 50% 
similarity to CRH. b Multiple alignment of the amino acid sequence of urocortin precursors from different species including some domestic animals. 
Rat mature Ucn1 has 99–100% similarity to dog, cow, horse, sheep, pig, alpaca, buffalo, and goat Ucn1. Ucn1 sequences have 99–100% similarity 
among different domestic animal species. Sequences were aligned using Clustal W then highlighted using BoxShade 3.21, which shades conserved 
residues according to whether they are completely conserved (black) or similar (gray). Hyphens indicate gaps in the sequence among the species. 
Asterisk indicates “predicted sequences”. c Binding affinity of CRHR-ligands. CRHR1 binds CRH as well as Ucn1, but not Ucn2 and Ucn3, whereas 
CRHR2 binds Ucns with a higher binding affinity than CRH. A proline residue at position 11 (bold letter) is found only in CRHR2-selective ligands, 
Ucn2 and Ucn3. These peptides also contain alanine residues at positions 35 and 39 (bold letters)
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for CRH, suggesting that these peptides may be its natu-
ral ligands [3, 8, 17, 18, 45, 48]. CRHR1 and CRHR2 are 
coded by two different genes. CRHR1 has been cloned 
in different mammalian species: humans, rats, mice, and 
sheep [18, 49–52]. The genes for human and rat CRHR1 
contain 14 and 13 exons, respectively [53, 54], and pro-
duce several alternatively spliced isoforms. In humans, 
eight CRHR1 isoforms have been described [18, 47, 55, 
56]. In rats, there are three CRHR1 isoforms [53]. In 
mice, there are four isoforms, equivalent to some human 
isoforms CRHR1alpha [50, 56]. The human CRHR2 gene 
contains 12 exons. Three major functional isoforms, 
alpha (411 amino acids), beta (438 amino acids), and 
gamma (397 amino acids), encoded by transcripts with 
alternative first exons [57] differ only in the N-terminal 
sequence comprising the signal peptide and part of the 
ECD (amino acids 18–108 of CRHR2 alpha). In mice, an 
mRNA splice variant of CRH-R2α (sCRH-R2α) was iden-
tified that encodes the receptor’s ligand-binding extracel-
lular domain but terminates before the transmembrane 
domains. This variant was therefore predicted to serve 
as a secreted decoy receptor, mimicking the ability of 
CRH-binding protein to sequester free CRH [58]. This 
soluble variant is efficiently translated but not necessarily 
secreted [59].
CRHBP is a 37-kDa glycoprotein and the bound form 
of CRH and its related peptides is biologically inactive 
[60]. CRHBP, in this manner, may have a role in modulat-
ing the effects of CRHR-ligand binding [20, 61]. Similar to 
CRH and CRHRs, CRHBP is widely distributed through-
out the brain [19]. In humans, but not known in rodents, 
CRHBP is also synthesized in the liver and placenta, 
and secreted into the general circulation. The presence 
of CRHBP in the CNS suggests that CRHBP may have 
additional roles. CRHBP also seems to facilitate some of 
the actions of CRH/Ucn1 in a CRHR2-dependent man-
ner. In particular, CRH requires CRH-BP to potenti-
ate NMDA receptors via CRHR2 in dopamine neurons 
[62]. Recently, Slater and colleagues demonstrated that 
CRF-BP acts as an escort protein for CRF2αR, facilitat-
ing its presence in the plasma membrane. These authors 
showed that CRF-BP physically interacts with CRF2αR in 
an isoform-specific manner, because no interaction was 
detected between CRF-BP and CRF2βR [63].
Activated CRHR1 and CRHR2 primarily signal by 
stimulating G protein (Gs) coupling, resulting in the 
induction of the cyclic adenosine monophosphate 
(cAMP)-protein kinase A (PKA) and the extracellular 
signal-regulated kinase-mitogen-activated protein kinase 
(ERK-MAPK) pathways. Activation of PKA leads to the 
phosphorylation of transcription factors like cAMP 
response element binding protein (CREB), which in turn 
increases the expression of downstream target genes [64]. 
CRHRs also interact with other G proteins, including Gq, 
Gi, and Gi1/2, thus activating phospholipase C variants 
(PLCs) and resulting in the activation of ERK1 and ERK2 
and an increase in intracellular  Ca2+ concentration [47, 
65]. Many other regulatory systems seem to modulate 
CRHR activity but are not well understood and warrant 
further study.
Hypothalamic–pituitary–adrenal and thyroid axis
Recent research has focused on possible roles played by 
Ucns and their cognate receptors CRHR1 and CRHR2, 
respectively on the HPA and thyroid axes. In particular, 
these studies demonstrated a relationship between their 
possible tissue distribution in these regions and their spe-
cific regulation in mammals.
Based on previous data reporting the role of CRH in 
multiple regulation mechanisms at the level of these 
regions and in consideration of the high correlation 
between Ucns and CRH, different studies have aimed to 
analyze the possible differences in the role of these pep-
tides with respect to CRH. Since the HPA axis plays a 
pivotal role in regulating fundamental processes of all liv-
ing organisms [66], the participation of these peptides in 
different activities of this system may be significant. It is 
well known that the HPA axis not only involves the func-
tions of three endocrine glands (hypothalamus, pituitary, 
and adrenal glands), but also is widely involved in dif-
ferent physiological processes such as regulation of the 
stress response [67], digestion, immune function, behav-
ior, sexuality, and energy storage and expenditure.
Similarly, the HPT axis plays a pivotal role in stimulat-
ing the normal secretion of thyroid hormone and thus 
contributes to maintain cardiovascular, bone, and liver 
function, and energy homeostasis [68]. Such complex 
activities of both the HPA and HPT axis are deeply con-
trolled by complex regulatory circuits that permit com-
munication between different regions, either through 
cell-to-cell communication (paracrine signaling) and 
within the same cell communication (autocrine signal-
ing). In this context, studies concerning Ucn distribution 
at the level of these endocrine axes in domestic animals 
(Table 1) indicate their possible involvement in regulating 
numerous biological functions. These findings could clar-
ify previous data reports often overshadowed by studies 
on CRH and its analogues, thus leaving aside many other 
angles of specific research.
Ucn1, the most-studied Ucn, has been characterized 
in terms of its localization in different domestic animal 
species, also focusing on its possible role in the CNS. In 
particular, Ucn1 identification in cats, particularly within 
the Edinger-Westphal (EW) nucleus [69], which differs 
from that observed in ovine species, where the peptide 
was observed in the hypothalamic region, could suggest 
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a particular role in this area as well as a specific bind-
ing activity towards CRH receptors, if compared with its 
homolog human Ucn1 [70].
Considering that in rats, Ucn1 localizes not only to the 
EW [71, 72] but also to lateral superior olivary (LSO) and 
supraoptic nuclei [73], the idea of a different modula-
tion in Ucn1 activity in domestic animal species should 
potentially be considered. The presence of Ucn1 in cats 
at the EW nucleus suggests a specific and confined role 
of this peptide, although the functional studies on this 
topic are limited. Moreover, it should be considered that 
the EW nucleus and the location of Ucn cell population 
differ among animal species (particularly between cats 
and macaque monkeys), although, as described for mon-
keys, in some cases, the distribution of the perioculomo-
tor (pIIIU) cell population is likely to overlap with that 
of C- and S-group motorneurons that supply non-twitch 
muscle fibers in the extraocular muscles [69]. This organ-
ization of Ucn cell populations and their projections 
suggest possible functional implications of Ucn1 and of 
the use of specialized neurotransmitters, that currently 
remain an open and testable hypothesis.
The direct activity of Ucn1 on ACTH release from the 
pituitary has been assessed in a complex research project 
in sheep focused on evaluating the endocrine effects of 
Ucn1 in experimental heart failure [67].
In contrast, in several studies conducted on rat species, 
the presence of Ucn1 mRNA in the brain and pituitary 
and the biological effects of Ucn1 after its intracere-
broventricular (ICV) or intravenous (IV) administration 
suggest its complex role in regulating the HPA axis [38, 
73].
In 2011, Ucn1 as well as its relative receptors 
CRHR1 and CRHR2 were isolated and characterized 
in the bovine adrenal gland, showing their particular 
distribution in both adrenal cortex and medulla [13]. 
Such results, confirmed by the use of histological and 
biochemical techniques, permit us to speculate about the 
role of Ucn1 in the intra-adrenal CRH-based regulatory 
system to be achieved by an autocrine mechanism [13]. 
Moreover, other data demonstrating the role of Ucn1 in 
adequate control of steroid secretion come from studies 
in lactating dairy cows with or without ovarian follicular 
cysts [74]. Together, these data confirm previous find-
ings obtained from studies using knockout (KO) mouse 
models lacking Ucn1, indicating cellular hypotrophy 
of the outer adrenal cortex and lower expression levels 
of Cyp11b2 [75]. However, Ucn1 knockout mice show 
no alterations in HPA axis activity [76, 77]. In addition, 
in mice deficient in Ucn2 or Ucn3, as single, double, or 
triple knockout in combination with Ucn1, alterations of 
HPA axis functions have not been observed [78–80]. The 
use of these models is undoubtedly important to clarify 
some metabolic functions of Ucns.
Studies conducted by directly administering Ucn1 have 
contributed to a better knowledge of the mechanisms 
exerted by Ucn1 and, in some cases, on its receptors 
CRHR1 and CRHR2 on the HPA axis of domestic animals 
(Table  2). In particular, Parrott et  al. [81] demonstrated 
that Ucn1, when administered by intracerebroventricular 
injection (ICV), induced an increase in cortisol secre-
tion similar to that induced by CRH, albeit the latter 
showed a higher stimulatory activity. Similar results were 
observed considering behavioral activation parameters 
(such as changes in posture and orientation, and engage-
ment in vigorous oro-nasal activity). The interpretation 
of these results should take into account that, in contrast 
to humans and rats, for which the CRHR distribution in 
the CNS has been identified [82], pig Ucn1 CRHR2 has 
not yet been discovered. Therefore, considering that 
Table 1 Expression of  urocortins (Ucns) and  their relative receptors, CRHRs, in  endocrine system tissues of  domestic 
animals
HPA hypothalamic–pituitary–adrenal axis, HPT hypothalamic-pituitary-thyroid axis, CL corpus luteum, n.d. not determined
Endocrine system Animal species Ucn1 Ucn2 Ucn3 CRHR1 CRHR2 References
HPA Cat + n.d. n.d. n.d. n.d. [67]
Bird n.d. n.d. + n.d. n.d. [153]
Cow + n.d. n.d. + + [13]
Sheep + n.d. n.d. n.d. n.d. [39, 68]
HPT Cow + n.d. n.d. + + [15]
Horse + n.d. n.d. + + [14]
Female gonads Pig (ovary-CL) + n.d. n.d. + + [117]
Pig (ovary) + n.d. n.d. + – [117]
Sheep (placentome) + n.d. n.d. + n.d. [126]
Male gonads Dog (testis) + n.d. n.d. + + [104]
Alpaca (epididymis) + n.d. n.d. + + [111]
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Ucn1 activity mostly occurs through CRHR2, the differ-
ent selectivity of CRHRs varies with animal species [83]. 
This last consideration could be important to evaluate 
the effect of Ucn1 in sheep, even if the recorded effects 
were similar between Ucn1 and CRF in this species [84].
The possibility of Ucn1 to exert its activities by binding 
to its specific CRHR2, which has not yet been identified 
in all tissues in different animal species, permits specula-
tion that Ucn1 exerts its activity in a broad range of areas. 
In particular, the integrative role of Ucn1 as a mediator in 
the interrelations between systems of appetite regulation, 
reproduction, growth, and metabolic balance has been 
evidenced in a study in gilts [85].
More recently, expression of Ucn1, CRHR1, and 
CRHR2 has been investigated in both equine and bovine 
thyroid glands [14, 15]. Such studies, supported by the 
use of multiple techniques (immunohistochemistry, 
western blotting, and RT-PCR), have greatly contributed 
to knowledge on the potential role of Ucn1 in this gland 
in domestic animals. In particular, in horses, immunohis-
tochemical results revealed for the first time that Ucn1 
expression specifically localizes in thyroid follicular cells, 
although CRHR2 was detected in both parafollicular and 
C-cells [14]. Results from bovine species [15] revealed a 
different distribution of Ucn1 and CRHR2 at the cellular 
level, confirmed by immunoreactivity in both follicular 
and parafollicular cells. Conversely, CRHR1 immunore-
activity was concentrated in the smooth musculature of 
blood vessels in both animal species, thus suggesting a 
potential role in modulating the thyroid gland blood flow, 
as previously reported in rats and mice [86–88].
In particular, western blotting showed that Ucn1 pre-
sents as a band corresponding to a molecular weight 
approximately of 16 kDa, comparable with the mamma-
lian Ucn precursor (122-amino acid protein) [8, 13, 43]. 
Its characterization suggests a role in calcitonin secretion 
via CRHR2 in an autocrine/paracrine manner, probably 
adjuvated by other CRHR2 ligands, such as Ucn2 and 
Ucn3. All these findings suggest a possible role of folli-
cular cells in regulating iodine uptake, supported by spe-
cific local blood flow. Such data confirm previous results 
by studies on pathological conditions in humans [89]. In 
particular, results from a case of multiple endocrine neo-
plasia type II showed the presence of cells highly express-
ing CRH, Ucn1, and Ucn3.
Together, these data indicate that CRH and Ucns play 
a role in secreting ACTH and glucocorticoid hormones. 
However, further studies are needed to investigate the 
possible involvement of Ucns in thyroid hormone syn-
thesis. Regarding the parathyroid, only a functional study 
by Asakawa et al. [90] demonstrated that the influence of 
parathyroid hormone-related protein on food intake by 
gastric emptying is related to Ucn2 and Ucn3 expression.
More recently, new promising perspectives regarding 
the involvement of Ucns (particularly Ucn2 and Ucn3) 
in the field of stress pathophysiology have been shown. 
This area of research is attractive considering that differ-
ent forms of stress (physical and psychological) interfere 
by multiple mechanisms (central and peripheral) on sev-
eral body activities (metabolism, reproduction, behavior, 
host defense, etc.). In this regard, although several stud-
ies on Ucn involvement in stress have been conducted in 
laboratory animals [78, 91–94], more research has been 
focused on domestic animals. Moreover, it should be 
taken into account that Ucns and CRH have been found 
in brain areas known to be important not only for body 
fluid and electrolyte homeostasis but also for behavior. In 
addition, Ucns (Ucn2 and Ucn3) seem to be particularly 
involved in regulating mammalian social behavior via 
activation of CRFR2 [95].
Some reports, based on results showing that stress 
can cause an increase in Na intake similar to the effect 
obtained by peripheral Ucn administration in several 
different species, including sheep [96], rabbits [97], rats 
Table 2 Effects of  administering urocortins (Ucns) and  their relative receptors, CRHRs, on  the  hypothalamic–pituitary–
adrenal axis of domestic animals
ICV intracerebroventricular, n.d. not determined, GH growth hormone, LH luteinizing hormone, ACTH adrenocorticotropic hormone
Animal species Treatment Ucn1 Ucn2 Ucn3 CRHR1 CRHR2 Effects References
Bird ICV n.d. n.d. + n.d. n.d. ↑ Ghrelin [154]
Ewe ICV + n.d. n.d. n.d. n.d. ↓ Food intake
↑ GH, LH, cortisol, leptin
[84]
Gilt ICV + n.d. n.d. n.d. n.d. ↓ LH and food intake
↑ Cortisol and ACTH
[85]
Horse (pony) ICV + n.d. n.d. n.d. n.d. ↑ Cortisol
↓ Food intake
[155]
Pig Central injection + n.d. n.d. + n.d. ↑ Cortisol [81, 156]
Sheep ICV + n.d. n.d. n.d. n.d. ↑ Urine excretion
↓ Food intake
[157]
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[98], and mice [99, 100], have stimulated interest on this 
research area. In sheep and rats, the appetite-related 
effects appear to occur via ACTH on adrenal gland hor-
mones, because it can be prevented by adrenalectomy 
[96, 98]. On the other hand, ACTH can cause an increase 
in Na intake in adrenalectomized wild rabbits [97]. Weis-
inger et  al. [101] demonstrated that Ucn, administered 
by ICV infusion, inhibited Na intake in sheep. In par-
ticular, Ucn inhibited not only need-free Na intake but 
also the high Na intake induced by peripheral ACTH, 
further indicating a definite inhibitory action. Taken 
together, these data suggest that Ucn and CRH can influ-
ence some, but not all, activities involved in Na appe-
tite—possibly only those initiated by corticosteroids. The 
mechanism remains to be clarified completely, because 
the brain nuclei that mediate Na appetite in sheep are not 
fully known. Presumably, other physiological processes 
entrained by stress that are important in determining the 
outcome on Na appetite need further investigation. In the 
meantime, studies in rats indicate that steroid-induced, 
but not Na depletion-induced, Na appetite is mediated 
in the medial amygdala [102], a brain area beyond the 
blood–brain barrier. Moreover, experiments analyzing 
the specific activity of urocortin with respect to the well-
known CRH, demonstrated that the two peptides could 
have both central and peripheral actions.
More recently, in a study regarding chronic social stress 
(CSS) in pigs that analyzed major factors driving gastro-
intestinal (GI) pathophysiology, Ucn2 mRNA was found 
to be up-regulated in the colon of pigs under CSS. These 
data have further confirmed the peripheral action of Ucn 
[103].
The data observed in domestic animal species could 
represent useful supporting evidence to that obtained in 
other species such as mice and rats, thus opening a new 
door to analyze the key role of Ucns related to biochemi-
cal, hormonal, and behavioral alterations in response to 
stress. The possible involvement of Ucns in the effects 
of stress should be of particular interest in farming ani-
mal species where specific conditions (food and/or water 
restriction or deprivation, social interaction, environ-
mental conditions, animal handling, etc.) can alter the 
normal body homeostasis, which affects various physio-
logical aspects and thus their performance. This concept 
also deserves further study, since Ucns may be involved 
in stress-related psycho-pathologies (depression and anx-
iety) [60], and discriminating between the specific action 
of Ucns might help determine their differential roles in 
regulating the stress response.
Gonads and reproductive system
Studies of the Ucns within the endocrine organs helped 
define the localization and physiological roles of these 
peptides and their receptors in the gonads and in diffuse 
cells of the reproductive system. The gonads play a piv-
otal role in regulating gametogenesis and steroidogene-
sis, thereby influencing reproductive performance. In this 
context, investigating Ucns in domestic and livestockin 
both healthy and pathological conditions might be rel-
evant for improving knowledge regarding reproduction, 
particularly in clinical practices. Few studies regarding 
the presence of Ucns and CRHRs in the male gonads 
of domestic animals have been performed, and one of 
these studies was conducted by our research group [104] 
(Table 1). We described Ucn1 and CRHRs in the testes of 
normal and cryptorchid dogs by means of immunohisto-
chemistry, western blot, and real-time RT-PCR. Particu-
larly, Ucn1 and CRHR2 were observed in the tubular and 
interstitial compartments of normal and cryptic gonads, 
leading us to hypothesize that these substances may play 
a role in regulating mitotic and apoptotic events occur-
ring during spermatogenesis and in regulating steroido-
genesis by an autocrine/paracrine mechanism. On the 
other hand, the distribution of CRHR1 in the muscu-
lar cells of blood vessels within the normal and cryptic 
gonads suggests a role of Ucn1, via CRHR1, in regulating 
canine testicular blood flow. The most interesting find-
ing of this research was a decrease in Ucn1 and CRHR2 
mRNA levels in cryptic canine testis, suggesting that 
these peptides play a role in preventing neoplasia. This 
last aspect deserves particular attention, as the Ucns 
could represent targets for possible pharmacological or 
therapeutic approaches for cryptorchidism, suggesting 
modulation of the main testicular functions, and conse-
quently, reproductive performance.
These hypotheses are based on published data in 
humans and rodents. The only evidence of Ucn1 and 
CRHRs in the human testis was demonstrated by Tezval 
et al. [105] who detected a possible role of these peptides 
in the pathophysiology of germ cell differentiation and 
division in normal adult and fetal testicular germ cell dis-
tribution. Most studies regarding Ucns and their recep-
tors in the male gonads were performed in rodents, with 
controversial results. Particularly, Ucn1 located in mouse 
spermatozoa had inhibitory effects on T-type calcium 
channels in mouse spermatogenic cells, sperm motil-
ity, and progesterone-evoked sperm acrosome reaction, 
indicating that inhibition of  Ca2+ channels might induce 
inhibitory effects of Ucn1 on male reproductive func-
tions [106]. In rat testis, intragastric alcohol injection 
significantly increased mRNA levels of testicular Ucn1, 
but not Ucn2, Ucn3, CRHR1, or CRHR2 [12]. Although 
McDowel et al. [107] demonstrated the ability of Ucn1, by 
binding CRHR1, to elevate steroidogenic gene expression 
in rat and mouse fetal Leydig cells, in the rat testes, this 
substance seemed to interfere with Leydig cell activity 
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by inhibiting human chorionic gonadotropin-stimulated 
steroidogenesis in primary adult rat Leydig cells [108]. 
However, Ucn1 may play a cytoprotective role in the 
germ cells from rat testis in response to ischemia–rep-
erfusion injury through activating major anti-apoptotic 
proteins, as well as by activating the MAPK signaling 
pathway [109]. Ucn-mediated steroidogenic/steroidolytic 
mechanisms could represent a starting point for study-
ing these substances in the reproductive sphere, regard-
ing the health and disease of domestic animals. It would 
be interesting to deepen our understanding about the 
implication of these peptides in stimulating or inhibit-
ing steroidogenic enzymes and subsequent repercussions 
on male fertility of domestic and farming animals, which 
would have great relevance for clinical practices, and 
eventually for therapeutic approaches. Currently, these 
remain only hypotheses.
Not only the male gonads, but also the diffuse “endo-
crine” cells, localized in the male genital tract participate 
in regulating reproductive functions. Particularly, Ucn1 
and CRHRs were also detected in some “endocrine” cells 
of male reproductive organs, such as the epididymis of 
rats [110] and alpacas (Vicugna pacos) (Table  1) [111], 
as well as normal, hyperplastic, and neoplastic pros-
tates in humans [112–114]. In the alpaca epididymis, 
Ucn1 and CRHR2 were found in the luminal portion of 
the epididymal principal cells, while CRHR1 was found 
in the fibromuscular cells encircling the epididymal 
tubules. Specifically, it has been hypothesized that Ucn1, 
via CRHR2, may be involved in absorptive and secretory 
activities of the luminal compartment of the epididymis. 
Moreover, via CRHR1, Ucn1 can modulate the contractil-
ity of this organ. On this basis, it might be hypothesized 
that Ucns in the epididymis could be involved in regulat-
ing male fertility, acting on the maturation and storage of 
spermatozoa and their transition throughout this organ. 
As in the human prostate, Ucns and their receptors 
might play multiple roles in regulation of prostate patho-
physiology in domestic and farming animals [112–115]; 
therefore, future studies should investigate these peptides 
in other animals.
The presence of Ucns in the female gonads of domes-
tic animals is unknown, while several studies were per-
formed on primates, humans, and rodents. To our 
knowledge, the only evidence of Ucns in the female 
reproductive system of domestic animals involves the 
porcine ovary, in which these peptides seemed to be 
mainly implicated in regulating steroidogenesis [116, 
117] (Table  1). Sakumoto et  al. [116] provided evidence 
for the existence of mRNAs encoding CRHR1 in the por-
cine corpus luteum (CL) throughout the estrous cycle. 
mRNA coding for CRHR1 was expressed at the highest 
levels in the CL of the regressed stage. CRH, via CRHR1, 
inhibited progesterone production by luteal cells while it 
did not affect estradiol-17β and prostaglandin F2α in this 
species. This research group suggested that CRH plays 
one or more roles in regulating porcine CL function dur-
ing the estrous cycle, especially at luteolysis (Table  1). 
Another important factor involved in ovarian function 
is microRNA-375 (miR-375). For this purpose, Yu et  al. 
[117] investigated the relationship between miR-375 
and CRH signaling molecules in the porcine ovary. PCR 
results showed that miR-375 and CRHR1 are expressed 
in the porcine ovary, whereas CRHR2 was not observed. 
These two factors seemed to be co-localized in ovarian 
granulosa cells, whereas CRHR1 was detected also in 
oocytes. The overexpression of miR-375 in cultured gran-
ulosa cells inhibits estrogen production. Thus, miR-375 is 
a key factor in regulating estrogen synthesis by mediating 
the CRH signaling pathway. The findings related to these 
substances in the female gonad of domestic animals are 
limited to CRH and its binding to cognate receptors.
In the ovarian CL of primates, Ucn1, Ucn2, CRHRs, 
and CRHBP were described [118, 119]. In primate spe-
cies, CRH/Ucns promoted luteal development and 
function but not the ovulatory process. In the human 
ovary, immunoreactive Ucn1 expression was found 
in luteinized granulosa and in theca cells of the func-
tioning and the regressing CL, and CRHRs were higher 
expressed in luteinized thecal cells of regressing CL. 
These findings suggested that Ucns and CRH were 
involved in suppressing steroidogenesis [120]. mRNAs 
encoding both CRHRs have been found during the 
late follicular phase in granulosa cells, interstitial cells 
in the ovarian stroma, and to a greater extent in theca 
cells of dominant follicles [120, 121]. The increased 
expression of CRHR1 observed in mature human folli-
cles implied a role of CRH-related peptides in follicu-
lar maturation [122]. Although initial studies failed to 
detect Ucn3 in the human ovary, it was later found in 
human granulosa-lutein cells of infertile women under-
going in  vitro fertilization [119] and it was hypoth-
esized to have an inhibitory effect on progesterone 
production [123]. Mouse models of both sexes over-
expressing Ucn2 exhibited significantly higher plasma 
Ucn2 levels and Ucn2 expression levels in the adrenals 
and ovaries [124]. Ucn2 overexpression in the ovaries 
decreased steroidogenesis and reduced the number 
of follicles that had undergone ovulation, which was 
not associated with reduced fertility. Ucn2, Ucn3, and 
CRHR1 expression was also identified in rat ovaries 
[45, 125]. The selectivity of the ovarian CRHR1 gene 
expression may suggest a biological action of CRH dur-
ing the ovulatory event within the rat gonadal life cycle, 
in both control and stressful conditions. In line with 
what is described in primates and rodents, it might be 
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hypothesized that even in domestic animals, CRH fam-
ily proteins could modulate ovarian steroidogenesis 
and ovulatory events, consequently affecting reproduc-
tive function. Currently, these are only hypotheses that 
would require investigation.
Ucns and CRHRs were also described in the placenta 
and uterus, where they are involved in several endocrine 
processes. There is only one published description of 
Ucns in the placenta of domestic animals. Particularly, 
CRH and Ucn1 have been identified in the ovine placen-
tome by immunohistochemistry [126] (Table 1). Most of 
the information related to this topic is limited to humans 
and rodents. Specifically, Ucn1, Ucn2, and Ucn3 were 
described in the human placenta and fetal membranes 
[127]. Ucn2 and Ucn3, found throughout human gestation 
in both the maternal and fetal membranes and decidua, 
have been described as regulators of placental vascular 
endothelial behavior and tone [128]. The different dis-
tribution of these peptides in the human gestational tis-
sues supports the hypothesis that they may serve different 
functions during pregnancy, although published data are 
still conflicting [129–131]. Similar profiles of Ucn2 mRNA 
and protein expression increase were assessed in mice 
during gestation, in which Ucn2 seemed to be implicated 
in the process of parturition [132]. In human trophoblast 
cell cultures, the endocrine actions of Ucn2, via CRHR2, 
include the regulation of aromatase activity and estrogen 
stimulation [133], and inhibition of placental 15-hydroxy-
prostaglandin dehydrogenase [134]. The immunoregu-
latory actions of Ucn2 also include amplification of 
placental lipopolysaccharide-induced [135] secretion of 
tumor necrosis factor (TNF)- and IL-10 [136]. These find-
ings suggest that Ucn2 contributes to placental regulation 
in pregnancy and parturition events.
Concerning the diffuse endocrine cells in the female 
reproductive system, Watanabe et  al. [31] detected 
Ucn2 in endometrial glands and epithelial cells of the 
rat uterus. mRNA levels of Ucn2 and CRHR2 in the 
uterus of mature rats were significantly higher in the 
diestrus phase than those in the proestrus phase, while 
plasma estrogen concentrations were significantly 
lower in the diestrus phase than in the proestrus phase. 
The uterine Ucn2/CRHR2 system might communicate 
with the estrogen system and may have regulatory roles 
in the estrous cycle. Ucn2 mRNA is strongly expressed 
in the uterus during the proliferative phase in healthy 
women, and this expression is abolished in patients 
with endometriosis [136]. In summary, the effects of 
Ucns on placental regulation, and in pregnancy and 
parturition events described in rodents and primates 
could be extended to farming animal species. Cows are 
frequently affected by retained fetal membranes, which 
represents a major problem in reproduction.
Digestive system
Extensive data on the distribution of Ucns and CRHRs in 
other organs suggest that these peptides have a more sig-
nificant role in regulating the diffuse endocrine system. 
In this context, the expression of Ucns and their recep-
tors as diffuse endocrine cells has mostly been found 
in the gastrointestinal tract of humans and rodents [45, 
137–146]. Few papers described the expression of Ucns 
and their receptors in the diffuse endocrine gastroin-
testinal system of domestic animals. Particularly, Ucn1, 
CRHR1, and CRHR2 were detected in the distal colon 
fetuses from ovine species, where they were expressed in 
many sites and particularly in diffuse endocrine epithe-
lial cells. Particularly, the co-localization of muscarinic 
receptor subtype M4 and weak CRHR2 signals on epithe-
lial cell surface of colon fetuses suggests that these two 
receptors may modulate ion transport functions of the 
M3 subtype receptor. Strong CRH signals in the cyto-
plasm of luminal colonocytes and moderate Ucn1 signals 
in epithelial cells indicate that both neuropeptides may 
regulate epithelial M3 receptor-mediated ion transport 
under stress conditions via CRHR2. In adult animals, 
stress is known to induce epithelial dysfunction (break-
ing of the epithelial barrier) including mucin secretion 
and transmucosal fluxes of macromolecules and elec-
trolytes [147, 148]. Reports describing the localization 
of CRH and Ucn1 in enterochromaffin cells and enteric 
neurons of rodents and humans indicate that endocrine 
and neural tissues may function as local sources for both 
neuropeptides to mediate gastric inhibitory and colonic 
stimulatory motility effects via autocrine or paracrine 
mechanisms [137, 138, 144].
In the digestive apparatus of mammals, the pancreas 
is a glandular organ whose endocrine cells are organized 
in small clusters, the islets. UCN3 is strongly expressed 
in mammalian pancreatic beta cells and has been shown 
to stimulate insulin secretion. The expression pattern of 
UCN3 differs considerably between rodent and primate 
islets. While mouse UCN3 is restricted to beta-cells [149, 
150], its expression in macaque (Macaca nemestrina) and 
human islets extends to the alpha-cells [149]. Consistent 
with this notion, Li et al. [150] have reported that exog-
enous UCN3, acting through CRHR2, stimulates insulin 
and glucagon secretion, particularly in the presence of 
nutrient excess. In rat and mouse insulin-secreting cell 
lines (INS-1 and MIN6), the expression levels of CRHR1 
are notably higher than levels of CRHR2, a balance that 
can be overturned by exposure to glucocorticoids (GCs) 
[41]. The plasma glucose concentration and pancreatic 
insulin and glucagon secretion are relevant in various 
physiological states of domestic animals (i.e. lactation 
in dairy cattle). Several neuroendocrine substances are 
involved in these states.
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Fig. 2 Illustration of the principal involvement of urocortins (Ucns) in regulating different endocrine organs
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Endothelium
Situated at the interface between the blood and the inner 
wall of the vasculature, the endothelium is currently con-
sidered as not only a protective barrier, but also a cen-
tral player that maintains cardiovascular homeostasis by 
secreting different substances. Ucn is one of these sub-
stances and has a dual effect on endothelium function 
[151, 152].
The endothelium, which also exhibits strong CRH-R2 
expression, may contribute significantly to Ucn-induced 
vasodilation in some situations; deendothelialization was 
reported to reduce the vasodilatory action of Ucn1 by as 
much as 50% in rat aorta [53]. Studies in rat and pig coro-
nary arteries [30, 69, 70] and human internal mammary 
arteries [73] indicate that Ucn1 endothelium–depend-
ent dilation involves both nitric oxide (NO) (via second 
messenger cyclic guanosine mono- phosphate), prosta-
glandins, and barium-sensitive and calcium-activated 
potassium channels. Ucn1-related vasodilation of renal 
arteries is reported to be mediated by the production of 
cAMP, synthesis and release of sarcoplasmic  Ca2+ as well 
as NO, and activation of potassium channels [74, 75].
Conclusions
The widely documented distribution of Ucns in differ-
ent tissues of domestic animals provides evidence for 
the important biological role of these peptides in regu-
lating bodily homeostasis. However, considering that 
more recent studies conducted on domestic animal spe-
cies have used Ucn administration to evaluate its effects, 
the results obtained from this approach do not always 
give a complete and clear pattern of activity. Indeed, it 
is important to analyze the convolution of all the possi-
ble conditions causing endogenous ligand release, which 
involves an orchestrated complex of stress mediators—
neurotransmitters, neuropeptides and steroids—that are 
released throughout the entire brain.
Moreover, considering the important involvement of 
Ucns in different physiological and pathophysiologi-
cal conditions related to the different endocrine glands 
(Fig.  2), they may be applied clinically to treat different 
diseases. This possibility is also derived from the wide 
spectrum of action shown by these neuropeptides at the 
central and peripheral level. Thus, future investigations 
addressing these aspects certainly could help fully char-
acterize these peptides.
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